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Background/Aims: Metallic stents designed to relieve 
malignant biliary obstruction are susceptible to occlusive 
tumor ingrowth or overgrowth. In a previous report, we de-
scribed metallic stents covered with paclitaxel-incorporated 
membrane (MSCPM-I, II) to prevent occlusion from tumor 
ingrowth via antitumor effect. This new generation paclitaxel-
eluting biliary stent is further endowed with sodium caprate 
(MSCPM-III) for enhanced drug delivery. The purpose of this 
study is to examine the safety of its drug delivery system in 
the porcine biliary tract. Methods: MSCPM-III (10% [wt/vol] 
paclitaxel) and covered metal stents (CMSs) were endoscopi-
cally inserted in porcine bile ducts in vivo. Histologic biliary 
changes, levels of paclitaxel released, and various serum 
analytes (albumin, alkaline phosphate, aspartate transami-
nase, alanine transaminase, total protein, total bilirubin, 
and direct bilirubin) were assessed. Results: Based on the 
intensity of reactive inflammation and fibrosis, changes in 
porcine biliary epithelium secondary to implanted MSCPM-
III were deemed acceptable (i.e., safe). Histologic features 
in the MSCPM-III and CMS groups did not differ significantly. 
In a related serum analysis, paclitaxel release from MSCPM-
III stents was below the limit of detection for 28 days. Bio-
chemical analyses were also similar for the two groups, and 
no evidence of hepatic or renal toxicity was found in animals 
receiving MSCPM-III stents. Conclusions: In a prototypic por-
cine trial, this newly devised metal biliary stent incorporating 
both paclitaxel and sodium caprate appears to be safe in the 
porcine bile duct. (Gut Liver 2019;13:471-478)
Key Words: Drug-eluting stent; Self expandable metallic 
stent; Drug delivery systems; Biliary tract neoplasms; Pancre-
atic neoplasm
INTRODUCTION
Biliary decompression is an important palliative treatment for 
patients with unresectable malignant biliary obstruction. In this 
setting, endoscopic drainage typically is more useful than surgi-
cal bypass,1 and a self-expandable metal stent (SEMS) is more 
effective than a plastic stent.2 Although a covered SEMS has 
been developed to deter occlusive tumor ingrowth after place-
ment, there has been no substantial improvement in terms of 
stent patency or migration stemming from either overgrowth/
ingrowth of tumor or biliary sludge.3,4 
To prevent occlusive tumor ingrowth, we developed an an-
titumor drug-eluting biliary stent,5-11 which is a metallic stent 
covered paclitaxel (PTX)-incorporated membrane (MSCPM). Its 
safety was confirmed through animal5-7 and human studies,8-11 
but its efficacy was unproven. This first-generation device failed 
to prevent tumor ingrowth, based on problematic biodegrada-
tion of polyurethane (PU) membranes,10 and the second-gener-
ation design (MSCPM-II) met with limited success in evaluating 
efficacy due to early stent occlusion (by food or sludge) or stent 
migration.11 However, there is a valid molecular rationale for 
combatting tumors through PTX-eluting membranes, and the 
MSCPM device has potential merit.12 
To address limitations of the MSCPM-II, a smooth luminal 
surface and antimigration flaps were added to the new MSCPM-
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III stent. Also, sodium caprate (SC) was included as a penetration 
enhancer to promote local antitumor effect and thus discour-
age occlusive tumor ingrowth. SC has been added to augment 
cancerous tissue penetration by PTX eluted from the MSCPM-III 
stent.13 SC is an agent known to heighten absorption of various 
drugs, such as ampicillin, insulin, low-molecular-weight hepa-
rin, and 5-fluorouracil.14 This study was conducted to evaluate 
the safety of the newly developed third-generation MSCPM-III 
stent in a porcine model, determining the feasibility of human 
application.
MATERIALS AND METHODS
1. Metal stent incorporating PTX- and SC-impregnated 
membranes 
Structural modifications were made to prevent early stent 
occlusion or migration. The MSCPM-II design is such that a 
membrane (Fig. 1A, b) is positioned between two layers of 
metal mesh (Fig. 1A, a). Thus, the luminal surface could become 
kinked and easily clogged by sludge or food (Fig. 1C). In the 
MPCPM-III stent, a layer of metal mesh is placed between two 
membranes (Fig. 1B) for a smooth lumen (Fig. 1D), and flaps 
were placed on both sides to prevent stent migration (Fig. 1E). 
The stent used for animal experiments was 6 mm in diameter 
and 2 cm in length when fully expanded. The delivery catheter 
used for animal experiments was 8.5 Fr, and the diameter of 
the stent was 2.8 mm before expansion and 6 mm at maximum 
expansion. After expanding the stent, the maximum expanding 
diameter was 6 cm in diameter and 2 cm in length, so the cross-
sectional area was about 376 mm2.
The membrane in this study has the same double-layer struc-
ture as that described previously.7 In the MPCPM-III stent, a 
layer of metal mesh was placed between two membranes (inner 
membrane, polytetrafluoroethylene [PTFE]; outer membrane, 
PU). The inner luminal aspect is composed of PTFE, which is 
resistant to bile acid, and the outer membrane is made of PU 
(Pellethane 2363-80A; Lubrizol Corp, Wickliffe, OH, USA). In 
addition to PTX 0.27 mg/cm2, SC (Sigma-Aldrich, St Louis, 
MO, USA) has been added to augment cancerous tissue pen-
etration by PTX (Samyang Biopharmaceuticals, Seoul, Korea) 
eluted from the MSCPM-III stent.13 The MSCPM-III stent coat-
ing consists of 400 mg (10%) PTX-SC-PU polymer and 10 mL 
tetrahydrofuran (THF) solution (Junsei Chemical, Tokyo, Japan) 
(PTX 40 mg+SC 40 mg+PU 320 mg+THF 10 mL). Control stents 
were coated with SC-PU polymer and THF (10 mL) only (SC 40 
mg+PU 360 mg+THF 10 mL). The coating process involves a 
rolling technique. 
2. Drug release profile 
This study used a stent that has been reported previously.13 In 
a previous study,13 stents coated with different amounts of SC (0, 
0.15, 0.32, and 0.51 mg/cm2) and a fixed amount (0.27 mg/cm2) 
of PTX were placed in 0.1% Tween 20-containing phosphate-
buffered saline solution and were incubated at 37°C in a shaking 
water bath at 50 rpm for 2 months to confirm the PTX-releasing 
behavior. The stent with PUSC10-PTX (SC 0.32 mg/cm2, PTX 
0.27 mg/cm2) exhibited optimal efficacy for drug penetration 
into the tumor, and thus it was applied in this animal study. The 
amount of PTX released was quantified using an HPLC-UV sys-
tem. The HPLC-UV analysis was performed at room temperature 
using a Thermo Scientific Hypersil C18 column (150×4.6 mm; 
Thermo Electron Co., Altrincham, UK). HPLC-grade methanol 
was the mobile phase delivered at a flow rate of 1 mL/min. PTX 
was detected at 227 nm.
The drug release profile was as follows. The stent was ini-
tially loaded with 0.27 mg/cm2 PTX, and the amount released 
in vitro for 2 months was measured. The total amount of PTX 
released over 2 months was 0.21±0.01 mg/cm2 (mean±standard 
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Fig. 1. Modification of metallic stent incorporating paclitaxel-impregnated membrane (MSCPM-III). (A) The previous MSCPM-II stent has two 
layers of metal mesh (a) with a single interposed membrane (b) leaving luminal mesh exposed. (B) In the MSCPM-III stent, metal mesh is flanked 
by two membranes, with no luminal mesh exposed. (C) Luminal roughness of the MSCPM-II stent encourages occlusion by sludge or food. (D) 
Smooth luminal surface of the MSCPM-III is less inclined to promote occlusion. (E) One of two flaps (white arrow) attached to the proximal aspect 
of the stent as an antimigration measure.
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deviation) PTX. The amount of PTX retained in the stent after 2 
months was 0.06±0.01 mg/cm2. Approximately 20% of the ini-
tial burst release of PU with PTX (PU-PTX) and PU with SC and 
PTX (PUSC-PTX) was detected at 2 days. After 2 days, approxi-
mately 2.5 μg/cm2 PTX was released daily from the PU-PTX 
and PUSC-PTX membranes. Secretion by the PTX-containing 
membrane was similar regardless of whether SC was added.
3. Experimental animals
Ten mini pigs (Sus scrofa domesticus, miniature pig, micro-
pig) ~12 months old and of average weight (40 kg [±20%]) were 
used as test (n=5) or control animals (n=5). Fasting was imposed 
24 hours before endoscopically advancing a stent into the bile 
duct of each animal. Anesthesia was induced by intravenous 
injection of ketamine hydrochloride (Yuhan Co, Seoul, Korea) 
and atropine sulfate (Daewon Pharmaceutical Co, Seoul, Korea), 
using ketamine hydrochloride for maintenance during the pro-
cedure. Each animal was placed in left lateral decubitus posi-
tion, orally inserting the stent to the level of ampulla via 3.8-mm 
retrograde pancreatic endoscope (ED-3630T video duodeno-
scope; Pentax Medical, Tokyo, Japan). Endoscopic clipping of 
the major duodenal papilla was performed using a conventional 
endoscope (GIF-Q260J; Olympus, Tokyo, Japan) with a fitted 
transparent cap (D-201; Olympus) as previously reported.15 The 
endoscope was positioned close to the major duodenal papilla 
such that the transparent cap was in contact with the papilla. 
The major papilla was partially ligated with one hemoclip (HX-
610-090L; Olympus) to prevent potential stent migration, and 
radiographs were taken to document stent placement. As the 
stent was inserted at the mid-CBD level, the distal migration of 
the stent from the upper side of the ampulla was confirmed by 
follow-up X-rays. Radiographs were obtained both immediately 
after stenting and after the stent was fully expanded. The esti-
mated diameters of the stents were 2.65±0.68 mm immediately 
after stenting and 5.74±0.36 mm after the stent was sufficiently 
expanded. Afterwards, antibiotics are administered for 3 days, 
and the animals were fed a standard diet for 4 weeks. The pigs 
were monitored daily for clinical symptoms and signs of death/
dying. Body weight was measured twice weekly at acquisition, 
assuming a once-weekly schedule during the purification pe-
riod, upon group assignment, before stent insertion, during the 
test period, and at the end of testing.
4. Extraction of specimens
After stenting and 4 weeks of monitoring, the animals were 
euthanized using a bolus of potassium chloride solution so that 
stents implanted endoscopically (including sites of insertion) 
could be studied. The pigs were anesthetized with 25 mg/mL 
tiletamine and 25 mg/mL zolazepam in a combination medica-
tion (Zoletil; Virbac, Carros, France) administered intramuscu-
larly. Anesthesia was maintained by inhalation of isoflurane. 
The abdomen was opened to confirm the position of the duode-
num. Stent-implanted bile ducts were sutured to the proximal 
portion of liver, marking the proximal aspect and leaving the 
stents intact. After fixation in 10% buffered neutral formalin 
and routine processing, histologic sections were prepared for 
examination. 
All experimental procedures were performed in accordance 
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Fig. 2. Histology of extracted com-
mon bile ducts showing similar 
inflammatory and fibrotic reactions 
after stenting with 0% paclitaxel 
(A) or 10% paclitaxel (B). Gross 
appearance (left panel) and corre-
sponding microscopic views (right 
panel: H&E, ×12.5), arrows indicate 
areas sampled for slide preparation. 
Proximal (a) and distal (e) portions 
of non-stented areas retain villous 
mucosal pattern in both groups, 
whereas proximal (b), central (c), 
and distal (d) portions of stented ar-
eas display luminal dilatation, mu-
cosal atrophy, and attenuated walls. 
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with rules of the Institutional Animal Care Committee and were 
approved by the Committee on Animal Research at Inha Uni-
versity (permit number: MK-IACUC 140620-001) and the Ani-
mal Protection Committee of the South Korean government. All 
surgery was performed under sodium pentobarbital anesthesia, 
and all efforts were made to minimize suffering.
5. Histologic analysis
Formalin-fixed common bile ducts were cross-sectioned at 
five levels and photographs were taken to document gross ap-
pearances of proximal and distal non-stented segments (a and 
e, left panel in Fig. 2A and B) and proximal, central, and distal 
stented segments (b, c, and d, left panel in Fig. 2A and B). A 
single pathologist evaluated the thickness of the epithelial lay-
ers, the degree of submucosal inflammatory cell infiltration 
and fibrotic accumulation in extracted tissues by hematoxylin 
and eosin staining (H&E). The thickness of each epithelial layer 
was defined as the distance between tissue protruding into the 
lumen and the lower portion of the submucosa. The basic cell 
types (i.e., monocytes), macrophages and foam cells were evalu-
ated by H&E staining.
6. Serum analysis
Blood samples were collected at 14 and 28 days after stent 
implantation for biochemical testing, immediately separating 
the serum by centrifugation (3,000 rpm, 10 minutes, 4°C). Lev-
els of albumin, alkaline phosphatase, aspartate transaminase, 
alanine transaminase, total protein, total bilirubin, and direct 
bilirubin were measured. 
Liquid chromatography was performed in tandem with mass 
spectrometry (LC-MS/MS) to determine serum PTX concentra-
tion. The calibration curve was prepared by adding docetaxel 
as internal standard to a PTX stock solution, and measuring 
various concentrations (5, 20, 50, 100, 200, 500 and 1,000 ng/
mL) in the same manner as blood analysis. Pretreatment of the 
blood was performed by solvent extraction method as follows: 
blood plasma (10 μL) and mobile phase (10 μL) containing the 
internal standard were vortexed; ethyl acetate (250 μL) was 
added to the blood sample and shaken, followed by centrifuga-
tion (14,000 rpm); and after centrifugation, the supernatant was 
decanted and dried, and 20 μL of mobile phase was added. The 
calibration curve thus obtained was linear in the test range and 
was y=0.0126×–0.0286 (R2=0.992).
7. Statistical analyses
Quantified serum analytes were compared using repeated 
ANOVA, and the results are expressed as means±standard de-
viation. All computations relied on SPSS version 12.0 (SPSS 
Inc, Chicago, IL, USA), setting significance at p<0.05.
Fig. 3. Common bile ducts (H&E, 
×12.5) showing histologic simi-
larities (luminal dilatation, mucosal 
atrophy, and attenuated walls) of 
both the control (A, B) and test 
groups (C, D), including damaged 
mucosal layers and denuded areas 
in contact with stents. (A, B) Dense 
cellularity of bile duct, with sharp 
nuclear staining across the top of 
areas in contact with stents (control 
specimen); and (C, D) loss of nuclear 
membranes and patchy fibrosis of 
the muscular layer across the bot-
tom of areas in contact with stents 
(test specimen); no necrosis or per-
foration of bile duct serosa.
A B
C D
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RESULTS
1. Outcome after stent insertion 
One occurrence each of stent migration and obstructive 
jaundice were recorded in the test group, and there were two 
stent migrations in the control group. The isolated instance of 
obstructive jaundice developed on day 10 after stent placement 
as a consequence of biliary ligation (during endoscopic stent-
ing) to prevent stent migration. However, food impaction or 
sludge-induced stent occlusion was not observed. The episode 
of stent migration occurred 2 weeks after insertion. However, no 
perforation or necrosis of bile duct occurred due to stenting. The 
final analysis was based on three test animals and three control 
animals.
2. Between-group histologic comparison
Stented areas (b, c, and d, left panel in Fig. 2A and B) had 
visibly larger luminal diameters and thinner walls than non-
stented areas (a and e, left panel in Fig. 2A and B), and mucosal 
surfaces in stented areas were flat and atrophic. Nevertheless, no 
perforation or necrosis was observed. These findings were com-
parable in both groups and were expected due to stent compres-
sion of bile duct walls. 
Microscopic examination of control stents showed that the 
mucosal lining of biliary duct was denuded (Fig. 3A and B) at 
areas in contact with stents, presumably a mechanical effect 
of stenting. This was true of both groups. In non-stented areas, 
mild-to-moderate inflammation, limited or no fibrosis, and 
varying degrees of mucosal sloughing or atrophy were observed. 
However, in PTX-eluting stents, the nuclear membranes of cells 
had disappeared, and patchy fibrosis was observed involving 
muscular layer of bile duct wall (Fig. 3C and D). This was pre-
sumptive cytotoxic effect of eluted PTX, intended to delay stent 
infiltration by bile duct cancer.
3. Serum analysis
Serum biochemical tests at the 2- and 4-week marks did not 
differ significantly in either group, nor were between-group dif-
ferences significant at these points in time (Fig. 4). In LC-MS/
MS analysis, the amount of liberated PTX in serum was reported 
as limit of detection.
DISCUSSION 
Although the first-generation MSCPM-I stent was found 
stable and effective in relieving malignant biliary obstruction 
during animal5 and preliminary human8 investigations, a com-
parator study in conjunction with non-drug-eluting covered 
metal stents did not confirm its efficacy.10 It seemed that tumor 
ingrowth was fostered by micro-imperfections and holes in the 
Fig. 4. Biochemical testing of serum: albumin (A), ALP (B), AST (C), ALT (D), total protein (E), and total bilirubin (F) measured at 2 and 4 weeks 
after stent implantation. The results were presented as the mean±SD. No significant differences in group outcomes were found between each mea-
surement at 2 and 4 weeks.
ALP, alkaline phosphatase; AST, aspartate transaminase; ALT, alanine transaminase. 
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PU membrane, and that PTX release was insufficient to ensure 
antitumor effect. To overcome these limitations, strategic uti-
lization of PTFE in the second-generation MSCPM-II device 
served to prevent biodegradation by bile acids, and another lay-
er of PU was added.7 Pluronic F-127 was also applied to prevent 
tumor ingrowth and progression through continuous, long-term 
release of high PTX concentrations. Again, the MSCPM-II was 
found safe in a prospective comparative human study, tested 
alongside conventional covered metal stents, but its efficacy 
could not be confirmed due to early stent occlusion (by food or 
sludge) or stent migration.11 The rough luminal surface of the 
MSCPM-II stent, rather than tumor ingrowth, was responsible 
for this problematic early occlusion.
As a third-generation device, the MSCPM-III stent was struc-
tured differently, sandwiching a core of metal mesh between 
two membranes to impart a smooth luminal surface. Antimigra-
tion flaps were also mounted on both sides to prevent migration 
of the covered SEMS, and SC was added to enhance penetration 
of PTX and boost antitumor effect. MSCMP-III is the same stent 
that has been reported previously.13 In the PTX-SC-PU mem-
brane, PTX was found to release for 60 days through in vitro 
drug release testing, without an initial burst.13 Long-term and 
continuous PTX release was achieved without Pluronic F-127 
by changing the drug-eluting membrane production method 
from a dipping method to a rolling technique. Ultimately, the 
penetration depth of PTX increased significantly in vivo and in 
vitro by adding SC.13
Biliary ductal attenuation, mild-to-moderate inflammation, 
limited or no fibrosis, and varying degrees of mucosal slough-
ing or atrophy in stented areas including anti-migration flap 
lesion were findings in MSCPM-III at this time, corresponding 
with those of previous animal studies.5,7 On the other hand, 
mucinous metaplasia and bile duct thickening observed in ani-
mal testing of the MSCPM-I stent5 and intestinal metaplasia 
developing during animal study of the MSCPM-II stent7 were 
not manifested in MSCPM-III-exposed tissues. Furthermore, the 
histological changes seen after MSCPM-I and MSCPM-II place-
ment were confined to the mucosal layer, whereas fibrosis in 
the deep muscle layer of the bile duct was apparent following 
MSCPM-III placement, indicating that PTX penetrated further 
using the MSCPM-III (enhanced by SC), even though all devices 
contained identical PTX concentrations. However, because we 
performed this study in normal bile ducts and did not evaluate 
the concentration of PTX in extracted bile ducts, we could not 
confirm the effectiveness of SC as a penetration enhancer. Nev-
ertheless, the serosa was not necrotic, and the fibrosis observed 
in deep muscle may be beneficial by acting as a physical barrier 
to tumor ingrowth, enhancing the localized inhibition of tumor 
invasion by PTX. 
The antimigration flaps attached to MSCPM-III stents were 
concerning. Despite this addition, the migration rate averaged 
30%: 20% (1/5 cases) in the test group and 40% (2/5 cases) in 
the control group. Although the MSCPM-III stent had a signifi-
cantly lower migration rate than the control stent, we cannot 
safely predict the migration rate in clinical practice because we 
used a pig model with normal bile ducts. In clinical settings, 
the migration rate would be expected to be lower because most 
patients will exhibit biliary strictures. By comparison, there 
were no instances of stent migration in animal testing of the 
MSCPM-II stents.7 One reason for such disparity is that the 
MSCPM-II stents were surgically inserted into bile ducts, leav-
ing ampulla intact but likely immobilizing the devices through 
incisional scarring and focal stenosis. Although migration was 
not encountered during animal testing, it did occur in clinical 
trials.11 On the other hand, when inserting the MSCPM-III stent 
after endoscopic cannulation of ampulla and sphincterotomy, 
the stent tends to easily migrate through ampulla.
Another explanation is that the radial force of the MSCPM-
III stent is weaker than that of the double-layered MSCPM-II. 
Low radial force of SEMS might be risk factor of migration.16 
The CBD diameters of mini pigs can be regarded as 3 to 4 mm 
in vivo.15 As in previous studies,5-7 the stents used in this study 
were 6 mm in diameter so that the diameter of stents might be 
suitable for bile ducts of experiment animals in this study. This 
appeared to be the result of a weakening of the stent radial force 
after modifying the stent structure. It is considered that the ra-
dial force of the single-layer structured MSCPM-III was reduced 
compared with that of the double-layer structured MSCMP-II. 
Such weakness could be a drawback in fixing the stent to bile 
duct. Finally, the smooth outer surface of the MSCPM-III device 
naturally may result in more migrations. Therefore, both the ra-
dial force and the antimigration flaps may need to be improved 
before further applications in human studies. Once modified, 
the migration rate in malignant biliary stenosis (unlike normal 
porcine duct) is expected to be low. Although the stent migra-
tion rate of the MSCPM-III did not reduce, the stent was not 
occluded by impacted food or sludge. In addition, severe com-
plications did not occur in the bile duct. Thus, the MSCPM-III is 
safe and can be confidently placed in humans.
If we anticipated stent migration in an animal after deploy-
ment, the ampulla was partially ligated using hemoclips. One of 
the pigs subjected to ligation later developed obstructive jaun-
dice and expired as an unfortunate and unavoidable complica-
tion. An alternative porcine biliary stricture model, using heat 
probes and radiofrequency ablation,17 was inappropriate for our 
purposes, given the detrimental effects on biliary histology. 
PTX concentration was assayed and various biochemical tests 
were performed to determine the systemic impact of its release 
by MSCPM-III stents. However, serum levels of PTX were too 
low for detection, confirming that only surrounding tissues are 
penetrated, with no systemic effects. In a previous human study 
involving 10% PTX,8 low levels of PTX (1.5×10–2 to 2.0×10–1 
mg/mL) was detected in the blood samples of patients for over 
50 days, but levels approximated the therapeutic range of PTX 
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(0.9×10–4 to 1.1×10–1 mg/mL), and there were no systemic ef-
fects of PTX. In the present study, biochemical analysis was 
performed to monitor PTX hepatotoxicity, but no abnormalities 
were identified in either the test group or in controls.
There were some limitations in this study. In this study, the 
PTX level in serum was measured, but the level released into the 
bile duct or remaining in the bile duct, urine, and feces could 
not be measured. As no PTX was released into the blood, it was 
not expected in urine or feces, but a limitation of the study is 
that we did not obtain all pharmacokinetic measurements. In 
the previous study,13 the release rate of PTX was high in the first 
few days; therefore, serum testing should have been performed 
during this period. However, in our animal experiment, the 
serum test proceeded at 2 weeks and there was a discrepancy 
between the in vitro and in vivo experiments. Although no fatal 
systemic complications occurred during the 4-week observa-
tion period, a limitation was that a systemic response was not 
confirmed at the time of the greatest release of PTX. Although 
the efficacy of SC in cancer has been documented in a previous 
study,13 we did not compare MSCPM-III (stent with PTX and SC) 
and MSCPM-III without SC. Therefore, we could not compare 
the effectiveness of SC as a penetration enhancer. Furthermore, 
because the present study was conducted in normal bile ducts, 
we could not confirm penetration of PTX into cancer tissue by 
SC. The uptake of PTX by penetration of SC may be different 
between normal and malignant bile ducts due to differences in 
physical properties (hydrophobicity, lipid content, water con-
tent, etc.) of the tissues; therefore, further studies are required. 
Based on these studies, it is expected that the anti-tumoral ef-
fect of PTX with penetration of SC on malignant bile ducts will 
be more clearly demonstrated.
In conclusion, drug-eluting stents designed to relieve ma-
lignant biliary obstruction have been modified and improved 
through the aid of animal studies and human clinical trials. The 
MSCPM-III stent with SC was developed to overcome the limi-
tations of its drug-eluting predecessors. This study confirms the 
histologic and systemic stability of the MSCPM-III stent in the 
porcine bile duct. Clinical studies are now needed to validate its 
safety and efficacy in patients. 
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